What’s new in pharmacokinetics of antimicrobials in AKI and RRT?

Intensive Care Medicine

Volumn 43, Issue 6, 2017, Pages 904-906

  Roberts, Jason A ^a,b   Lefrant, Jean Yves ^c,d   Lipman, Jeffrey ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

Antibiotic; Antibiotic resistance; Dialysis; Dosing; Pharmacodynamics

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CREATININE; LINEZOLID; MEROPENEM; PIPERACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG MONITORING; FLOW RATE; HEPATIC CLEARANCE; HUMAN; KIDNEY FUNCTION; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION; DOSE RESPONSE; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL REPLACEMENT THERAPY;

EID: 85017165172     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-017-4789-x     Document Type: Article

References (15)

1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813–818
2. Jamal JA, Udy AA, Wallis SC, Ranganathan D, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2015) Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin? Int J Artif Organs 38:419–424
3. Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med 42(7):1640–1650
4. Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators (2015) A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care 19:84
5. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627–1638
6. Muhl E, Martens T, Iven H, Rob P, Bruch HP (2000) Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56:671–678
7. Karaiskos I, Friberg LE, Galani L, Ioannidis K, Katsouda E, Athanassa Z, Paskalis H, Giamarellou H (2016) Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 48:337–341
8. Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 60:4901–4909
9. Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, Roberts JA (2016) Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. J Antimicrob Chemother 71:1643–1650
10. Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother 71:464–470
11. Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodriguez AH, Pontes C, Calvo G, Torres A, Martin-Loeches I (2015) Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 59:5520–5528
12. Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, Aduroja OA, Amde M, Groszek JJ, Wei P, Taylor ME, Tolwani AJ, Fissell WH (2016) Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing CRRT. Clin J Am Soc Nephrol 11:1377–1383
13. Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Wallis SC, Lipman J, Roberts JA (2015) Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 45:41–45
14. Jamal JA, Roberts DM, Udy AA, Mat-Nor MB, Mohamad-Nor FS, Wallis SC, Lipman J, Roberts JA (2015) Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 46:39–44
15. Brasseur A, Hites M, Roisin S, Cotton F, Vincent JL, De Backer D, Jacobs F, Taccone FS (2016) A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother 71:1386–1394